Phase II Trial of Neoadjuvant/Adjuvant Imatinib Mesylate (IM) for Advanced Primary and Metastatic/Recurrent Operable Gastrointestinal Stromal Tumor (GIST) – early results of RTOG 0132

Схожие документы

• Phase II Trial of Neoadjuvant/adjuvant Imatinib Mesylate for Advanced Primary and Metastatic/recurrent Operable Gastrointestinal Stromal Tumors: Long-term Follow-up Results of Radiation Therapy Oncology Group 0132
  по: Wang, Dian, et al.
  Опубликовано: (2011)
• Adjuvant and Neoadjuvant Imatinib Therapy: Current Role in the Management of GIST
  по: Eisenberg, Burton L, et al.
  Опубликовано: (2011)
• Preoperative imatinib mesylate (IM) for huge gastrointestinal stromal tumors (GIST)
  по: Tang, Sumin, et al.
  Опубликовано: (2017)
• ACRIN 6665/RTOG 0132 Phase II Trial of Neoadjuvant Imatinib Mesylate for Operable Malignant Gastrointestinal Stromal Tumor: Monitoring with (18)F-FDG PET and Correlation with Genotype and GLUT4 Expression
  по: Van den Abbeele, Annick D., et al.
  Опубликовано: (2012)
• Placebo-Controlled Randomized Trial of Adjuvant Imatinib Mesylate Following the Resection of Localized, Primary Gastrointestinal Stromal Tumor (GIST)
  по: DeMatteo, Ronald P., et al.
  Опубликовано: (2009)